Chirally Controlled Oligonucleotides for Allele-Specific HTT Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Huntington's disease are lacking, particularly due to the instability of naturally occurring nucleic acids against nucleases and poor cell penetration, which limits their therapeutic efficacy.
Innovation Solution
The development of WVE-003, a chirally controlled oligonucleotide with specific structural modifications, including 2′-OMe, Rp phosphorothioate linkages, and 5-methyl 2′-O-methoxyethyl C, which is administered to selectively reduce mutant HTT protein levels while retaining wild-type HTT levels, using allele-specific knockdown technology targeting the mutant huntingtin gene transcript.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If naturally occurring nucleic acids are used for therapeutics, then the treatment approach is simple and straightforward, but the stability against nucleases and cell penetration are poor
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleic acids through various modifications including 2'-O-methyl, phosphorothioate linkages, and 5-methyl 2'-O-methoxyethyl C. These chemical parameter changes enhance stability against nucleases while maintaining therapeutic functionality, directly resolving the contradiction between simplicity and stability.
Solution Approach 2:
The invention creates composite oligonucleotide structures combining multiple modified nucleoside types (2'-OMe, phosphorothioate, 5-methyl 2'-O-methoxyethyl C) to achieve enhanced stability and cell penetration. This composite approach allows the therapeutic to maintain simplicity of use while achieving superior reliability through combined chemical modifications.
2Ease of manufacture
If naturally occurring nucleic acids are used for therapeutics, then the treatment approach is simple, but the cell penetration is poor
Solution Approach 1:
The patent modifies physical-chemical parameters of the nucleic acid backbone and sugar moieties (2'-O-methyl, phosphorothioate, 2'-O-methoxyethyl) to enhance cell membrane penetration capability while preserving the overall therapeutic approach simplicity.
3Reliability
If structural modifications are made to HTT oligonucleotides, then stability and therapeutic properties are improved, but the structural complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific chemical modifications at particular positions within the oligonucleotide sequence (2'-O-methyl at sugar positions, phosphorothioate at backbone linkages, 5-methyl 2'-O-methoxyethyl C at cytosine positions). This localized modification approach improves stability without uniformly complicating the entire structure, allowing targeted enhancement where needed.
4Reliability
If allele-specific knockdown is achieved, then selective reduction of mutant HTT is improved, but the precision of targeting increases
Solution Approach 1:
The patent utilizes feedback mechanisms through allele-specific design where the oligonucleotide sequence is tailored to match specific mutant HTT alleles (such as those with expanded CAG repeats). The design incorporates feedback from known allele variations to achieve selective knockdown, improving reliability while managing the precision requirements through targeted sequence selection.
Data Source
AI summary
Among other things, the present disclosure provides various oligonucleotide technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing such oligonucleotide compositions. In some embodiments, a method is a method of treatment or prevention of Huntington's Disease in a subject in need thereof; a method of allele-specific knockdown of a mutant Huntingtin transcript in a subject; a method for delaying the onset of and/or reducing the severity of at least one symptom of Huntington's Disease in a subject with Huntington's Disease; a method of reducing the expression, level, amount and/or activity of a mutant Huntingtin gene or a gene product thereof; and/or a method of preparation of a medicament for treatment of Huntington's Disease, wherein the method pertains to the use of an oligonucleotide described herein, administered at a dose described herein. In some embodiments, the present disclosure provides doses, dosages, and formulations of an oligonucleotide described herein.